重症酒精性肝炎治疗进展*

doi:10.3969/j.issn.1672-5069.2016.01.034

摘要/Abstract

摘要： 酒精性肝病在我国逐年增多,重症已成为肝衰竭的重要病因。本文就重症酒精性肝炎SAH的治疗进展进行介绍。戒酒和营养支持是SAH治疗的基础。激素、己酮可可碱、N-乙酰半胱氨酸、TNF-α抑制剂等干预性治疗手段在不断研究,但确切疗效尚存在争议,尚需要进一步高水准的临床观察验证。肝移植治疗是晚期酒精性肝炎患者的有效治疗方式,然而由于移植后复饮的问题,移植术前应进行严格的评估。

关键词: 重症酒精性肝炎, 治疗, 综述

Abstract: The cornerstone of therapy for alcoholic hepatitis are abstinence and nutritional support. Many therapeutic interventions have been studied in alcoholic hepatitis but have been unable to show convincing benefit. These interventions included, Corticosteroids,Pentoxifylline,N-acetylcysteine,inhibitors of TNF-α,etc. High quality clinical trials research is essential in China. Liver transplantation（LT） confers a survival benefit in patients with ALD. However,alcohol relapse after transplantation remains a critical issue and drinking habits of transplanted patients need to be routinely screened.

Key words: Severe alcoholic hepatitis, therapy, review

朱冰, 刘利敏综述, 刘鸿凌审校. 重症酒精性肝炎治疗进展^*[J]. 实用肝脏病杂志, 2016, 19(1): 117-120.

Zhu Bing, Liu Limin, Liu Honglin. Research advances in severe alcoholic hepatitis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(1): 117-120.

参考文献

[1] 厉有名,范建高,王炳元,等. 酒精性肝病诊疗指南. 临床肝胆病杂志,2010,21（3）:229-232.
[2] Spengler EK,Dunkelberg J,Schey R. Alcoholic hepatitis:current management. Dig Dis Sci,2014,59（10）:2357-2366.
[3] EASL clinical practical guidelines:management of alcoholic liver disease. J Hepatol,2012,57（2）:399-420.
[4] 厉有名. 酒精性肝病的流行病学及自然史. 中华肝脏病杂志, 2010,18（3）:171-172.
[5] Mann RE,Smart RG,Govoni R. The epidemiology of alcoholic liver disease. Alcohol Res Health,2003,27（3）:209-219.
[6] Sussman S,Dent CW,Skara S,et al. Alcoholic liver disease （ALD）:a new domain for prevention efforts. Subst Use Misuse, 2002,37（14）:1887-1904.
[7] 厉有名,陈卫星,虞朝辉,等. 浙江省酒精性肝病流行病学调查概况. 中华肝脏病杂志,2003,（11）:9-11.
[8] 全国酒精性肝病调查协作组. 全国酒精性肝病的多中心调查分析. 中华消化杂志,2007,27（4）:231-234.
[9] S You,Y Rong,B Zhu,et al. Changing etiology of liver failure in 3,916 patients from northern China:a 10-year survey. 2013.
[10] 朱冰,游绍莉,刘鸿凌,等. 623例老年肝衰竭病因学及预后分析. 解放军医学杂志,2014,（8）:624-627.
[11] Xie YD,Feng B,Gao Y,et al. Effect of abstinence from alcohol on survival of patients with alcoholic cirrhosis:A systematic review and meta-analysis. Hepatol Res,2013.
[12] Muntaner L,Altamirano JT,Augustin S,et al. High doses of beta-blockers and alcohol abstinence improve long-term rebleeding and mortality in cirrhotic patients after an acute variceal bleeding. Liver Int,2010,30（8）:1123-1130.
[13] Bardou-Jacquet E,Legros L,Soro D,et al. Effect of alcohol consumption on liver stiffness measured by transient elastography. World J Gastroenterol,2013,19（4）:516-522.
[14] Tsiaousi ET,Hatzitolios AI,Trygonis SK,et al. Malnutrition in end stage liver disease:recommendations and nutritional support. J Gastroenterol Hepatol,2008,23（4）:527-533.
[15] Plauth M,Cabre E,Riggio O,et al. ESPEN Guidelines on Enteral Nutrition:Liver disease. Clin Nutr,2006,25（2）:285-294.
[16] Ramond MJ,Poynard T,Rueff B,et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med,1992,326（8）:507-512.
[17] Rambaldi A,Saconato HH,Christensen E,et al. Systematic review:glucocorticosteroids for alcoholic hepatitis-a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther,2008,27（12）:1167-1178.
[18] O'Shea RS,Dasarathy S,McCullough AJ. Alcoholic liver disease. Am J Gastroenterol,2010,105（1）:14-32;quiz 33.
[19] Louvet A,Wartel F,Castel H,et al. Infection in patients with severe alcoholic hepatitis treated with steroids:early response to therapy is the key factor. Gastroenterology,2009,137（2）:541-548.
[20] Louvet A,Naveau S,Abdelnour M,et al. The Lille model:a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology,2007,45（6）:1348-1354.
[21] Mathurin P,Louvet A,Duhamel A,et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis:a randomized clinical trial. JAMA,2013,310（10）:1033-1041.
[22] Whitfield K,Rambaldi A,Wetterslev J,et al. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev,2009,（4）: CD007339.
[23] Lee WM,Hynan LS,Rossaro L,et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009,137（3）:856-864.
[24] Akriviadis E,Botla R,Briggs W,et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis:a double-blind,placebo-controlled trial. Gastroenterology,2000,119（6）:1637-1648.
[25] Higuera-de la Tijera F,Servin-Caamano AI,Cruz-Herrera J, et al. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Ann Hepatol,2014,13（3）:343-352.
[26] Stewart S,Prince M,Bassendine M,et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol,2007,47（2）:277-283.
[27] 林伟,张晶,段钟平. N-乙酰半胱氨酸治疗重症肝病的多中心前瞻性临床研究. 山东医药,2008,48（19）:3-5.
[28] Ambade A,Mandrekar P. Oxidative stress and inflammation: essential partners in alcoholic liver disease. Int J Hepatol, 2012,2012（85）:71-75.
[29] Phillips M,Curtis H,Portmann B,et al. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis-a randomised clinical trial. J Hepatol,2006,44（4）:784-790.
[30] Nguyen-Khac E,Thevenot T,Piquet MA,et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med,2011,365（19）: 1781-1789.
[31] Thakur V,Pritchard MT,McMullen MR,et al. Chronic ethanol feeding increases activation of NADPH oxidase by lipopolysaccharide in rat Kupffer cells:role of increased reactive oxygen in LPS-stimulated ERK1/2 activation and TNF-alpha production. J Leukoc Biol,2006,79（6）:1348-1356.
[32] Albano E,Vidali M. Immune mechanisms in alcoholic liver disease. Genes Nutr,2010,5（2）:141-147.
[33] Mottaran E,Stewart SF,Rolla R,et al. Lipid peroxidation contributes to immune reactions associated with alcoholic liver disease. Free Radic Biol Med,2002,32（1）:38-45.
[34] Boetticher NC,Peine CJ,Kwo P,et al. A randomized,double-blinded,placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology,2008,135（6）:1953-1960.
[35] Ki SH,Park O,Zheng M,et al. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding:role of signal transducer and activator of transcription 3. Hepatology,2010,52（4）:1291-1300.
[36] Burra P,Senzolo M,Adam R,et al. Liver transplantation for alcoholic liver disease in Europe:a study from the ELTR（European Liver Transplant Registry）. Am J Transplant,2010,10（1）:138-148.
[37] Vanlemmens C,Di Martino V,Milan C,et al. Immediate listing for liver transplantation versus standard care for Child-Pugh stage B alcoholic cirrhosis:a randomized trial. Ann Intern Med,2009,150（3）:153-161.
[38] DiMartini A,Day N,Dew MA,et al. Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liver Transpl,2006,12（5）:813-820.
[39] Mathurin P, Moreno C,Samuel D,et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med,2011,365（19）:1790-1800.
[40] Dominguez M,Miquel R,Colmenero J,et al. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology,2009,136（5）: 1639-1650.
[41] Colmenero J,Bataller R,Sancho-Bru P,et al. Hepatic expression of candidate genes in patients with alcoholic hepatitis:correlation with disease severity. Gastroenterology,2007,132（2）:687-697.
[42] Charbel Issa P,Chong NV,Scholl HP. The significance of the complement system for the pathogenesis of age-related macular degeneration-current evidence and translation into clinical application. Graefes Arch Clin Exp Ophthalmol,2011,249（2）:163-174.
[43] Mencin A,Kluwe J,Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut,2009,58（5）:704-720.
[44] Bass NM,Mullen KD,Sanyal A,et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med,2010,362（12）:1071-1081.
[45] Feldstein AE,Gores GJ. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci,2005,10:3093-3099.
[46] Ribeiro PS,Cortez-Pinto H,Sola S,et al. Hepatocyte apoptosis, expression of death receptors,and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol,2004,99（9）:1708-1717.
[47] Seth D,Gorrell MD,Cordoba S,et al. Intrahepatic gene expression in human alcoholic hepatitis. J Hepatol,2006,45（2）:306-320.
[48] Tam J,Liu J,Mukhopadhyay B,et al. Endocannabinoids in liver disease. Hepatology,2011,53（1）:346-355.
[49] Louvet A,Teixeira-Clerc F,Chobert MN,et al. Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology,2011,54（4）:1217-1226.
[50] Mookerjee RP,Wiesenthal A,Icking A,et al. Increased gene and protein expression of the novel eNOS regulatory protein NOSTRIN and a variant in alcoholic hepatitis. Gastroenterology. 2007,132（7）:2533-2541.

重症酒精性肝炎治疗进展^*

Research advances in severe alcoholic hepatitis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[3]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[4]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[5]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[6]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[7]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[8]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[9]	冯文广, 姜伟, 宋国军. PPV指导术中液体治疗对行肝部分切除术治疗的肝内胆管结石患者术后并发症发生的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 912-915.
[10]	黎秋曦, 贾健锋, 黄锐. 区段肝蒂肝切除术与B超引导下肝切除术治疗肝胆管结石患者临床价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 916-919.
[11]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[12]	张瑞, 王剑, 陈世耀. 肝硬化门脉高压症并发血栓形成机制和治疗研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 930-933.
[13]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.
[14]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[15]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.